Velsera was formed in 2023 through the shared vision of Seven Bridges and Pierian, with a mission to accelerate the discovery, development, and delivery of life-changing insights. Velsera provides software and professional services for: • Multimodal Data Harmonization & Analytics for Drug Discovery & Development • IVD Development, Validation & Approval • Clinical NGS Interpretation, Reporting & Adoption Join our community (support.velsera.com/hc/en-us/community/topics) and explore our solutions (velsersa.com/solutions). Let's drive the future of precision medicine - together.
| Website | http://velsera.com |
| Revenue | $43.7 million |
| Employees | 419 (224 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
| Keywords | Precision Medicine, Healthcare, Healthcare Innovation, Life Sciences, Scientific Research, Medical Research, Data Analytics, Research, Medical Technology, Health Informatics, Translational Medicine, Biotechnology, Clinical Trials, Big Data, Clinical Development, Pharmaceutical, Drug Discovery, Bioinformatics, Genomics, Proteomics |
| Competitors | Thermo Fisher Scientific, Agilent Technologies, Illumina, QIAGEN, GRAIL, DNAnexus, HudsonAlpha Institute for Biotechnology, Bionano Genomics, Inc., CureMetrix, Base Genomics +35 more (view full list) |
Looking for a particular Velsera employee's phone or email?
The Velsera annual revenue was $43.7 million in 2026.
Jamie Coffin is the Chief Executive Officer and Board Member of Velsera.
224 people are employed at Velsera.